.webp)
67/100B67.290
USD
-0.26
(-0.38%)
Post Trading·68.800USD+1.510(+2.24%)
Last updated: · Delayed 15 min
Fair value63.11Plus+7%48Price 67.2994
Q4 FY2026 · Earnings report
EPS estimate 1.53Revenue estimate 960.74M
Q4 FY2026 · Earnings report
EPS estimate 1.53Revenue estimate 960.74M
Royalty Pharma operating income 2015–2026What are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
Royalty Pharma's operating income in Q3 FY2026, the three months to 30 September 2026, was 411.00M USD, with no change to compare on the same quarter a year before. Royalty Pharma's operating income in fiscal year 2025 was 1.56B USD, up 20.7% on the year before.
Last updated 6 Nov 2026 · Next report 10 Feb 2027
Operating income
Operating income · +7.0% a year over 10 yearsOperating margin
Growth
| Fiscal year | Period ending | Operating income | Growth | Operating margin | Gross profit | Gross margin | EBITDA |
|---|---|---|---|---|---|---|---|
| TTM | 30 Sept 2026 | — | — | — | — | — | — |
| FY2025 | 31 Dec 2025 | 1.56B | +20.66% | 65.58% | 2.38B | 100.00% | 1.64B |
| FY2024 | 31 Dec 2024 | 1.29B | -13.38% | 57.10% | 2.26B | 100.00% | 1.56B |
| FY2023 | 31 Dec 2023 | 1.49B | +385.94% | 63.37% | 2.35B | 100.00% | 1.89B |
| FY2022 | 31 Dec 2022 | 307.07M | -78.54% | 13.73% | 2.24B | 100.00% | 423.70M |
| FY2021 | 31 Dec 2021 | 1.43B | -10.32% | 62.49% | 2.29B | 100.00% | 1.43B |
| FY2020 | 31 Dec 2020 | 1.60B | -39.18% | 75.17% | 2.12B | 100.00% | 1.88B |
| FY2019 | 31 Dec 2019 | 2.62B | +92.25% | 144.59% | 1.81B | 100.00% | 2.75B |
| FY2018 | 31 Dec 2018 | 1.36B | +45.20% | 76.02% | 1.79B | 100.00% | 1.83B |
| FY2017 | 31 Dec 2017 | 939.69M | +29.99% | 58.81% | 1.60B | 100.00% | 1.62B |
| FY2016 | 31 Dec 2016 | 722.87M | -8.99% | 38.50% | 1.88B | 100.00% | 1.07B |
| FY2015 | 31 Dec 2015 | 794.28M | — | 48.07% | 1.65B | 100.00% | 862.44M |
| Quarter | Period ending | Operating income | Growth on a year before | Operating margin | Gross profit | Gross margin | EBITDA |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 411.00M | — | 59.57% | 628.00M | 91.01% | 357.00M |
| Q2 FY2026 | 30 Jun 2026 | 133.00M | — | 19.73% | 405.93M | 60.21% | 176.40M |
| Q1 FY2026 | 31 Mar 2026 | 632.48M | — | 100.30% | 629.41M | 99.81% | 563.15M |
| Q4 FY2025 | 31 Dec 2025 | — | — | — | — | — | — |
| Q3 FY2025 | 30 Sept 2025 | — | — | — | — | — | — |
| Q2 FY2025 | 30 Jun 2025 | — | — | — | — | — | — |
| Q1 FY2025 | 31 Mar 2025 | — | — | — | — | — | — |
| Q4 FY2024 | 31 Dec 2024 | — | — | — | — | — | — |
| Q3 FY2024 | 30 Sept 2024 | — | — | — | — | — | — |
| Q2 FY2024 | 30 Jun 2024 | — | — | — | — | — | — |
| Q1 FY2024 | 31 Mar 2024 | — | — | — | — | — | — |
| Q4 FY2023 | 31 Dec 2023 | — | — | — | — | — | — |
| Q3 FY2023 | 30 Sept 2023 | — | — | — | — | — | — |
| Q2 FY2023 | 30 Jun 2023 | — | — | — | — | — | — |
| Q1 FY2023 | 31 Mar 2023 | — | — | — | — | — | — |
| Q4 FY2022 | 31 Dec 2022 | — | — | — | — | — | — |
| Q3 FY2022 | 30 Sept 2022 | — | — | — | — | — | — |
| Q2 FY2022 | 30 Jun 2022 | — | — | — | — | — | — |
| Q1 FY2022 | 31 Mar 2022 | — | — | — | — | — | — |
| Q4 FY2021 | 31 Dec 2021 | — | — | — | — | — | — |
| Q3 FY2021 | 30 Sept 2021 | — | — | — | — | — | — |
| Q2 FY2021 | 30 Jun 2021 | — | — | — | — | — | — |
| Q1 FY2021 | 31 Mar 2021 | — | — | — | — | — | — |
| Q4 FY2020 | 31 Dec 2020 | — | — | — | — | — | — |
| Q3 FY2020 | 30 Sept 2020 | — | — | — | — | — | — |
| Q2 FY2020 | 30 Jun 2020 | — | — | — | — | — | — |
| Q1 FY2020 | 31 Mar 2020 | — | — | — | — | — | — |
| Q4 FY2019 | 31 Dec 2019 | — | — | — | — | — | — |
| Q3 FY2019 | 30 Sept 2019 | — | — | — | — | — | — |
| Q2 FY2019 | 30 Jun 2019 | — | — | — | — | — | — |
| Q1 FY2019 | 31 Mar 2019 | — | — | — | — | — | — |
Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.
See also:Revenue,Net income,EPS,Shares outstanding,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement
Common questions about Royalty Pharma's operating income
Source: Financial Modeling Prep